NetworkNewsBreaks Archive - Page 1919 of 1951

FridayDec 23, 2016 9:38 am

NetworkNewsBreaks – inTEST Corp.’s (NYSE: INTT) Thermal Division Drives Accelerated Q3 Financial Performance

inTEST (NYSE MKT: INTT) designs, manufactures and markets products that are used primarily by semiconductor manufacturers to test their integrated circuits and wafer products. The company’s solutions stem from two product segments: inTEST EMS products and inTEST thermal solutions. In its recent third-quarter financial report, inTEST attributes its improved performance to strength in the Thermal division, which had revenue growth of nearly 20% over the previous quarter. Third-quarter net revenues were $10.8 million compared to $9.2 million in the comparable quarter of 2015. Third quarter net earnings were $1.1 million, or $0.11 per diluted share, compared with net earnings of $310,000,…

ThursdayDec 22, 2016 3:12 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on December 22, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: SPRS 28.62% – News: Reaches agreement with investors for outstanding shares TRCK 12.00% – News: Posts fiscal 2016 financial results SIRC 8.51%– News: Names new VP of sales AMEH 5.26% – News: Signs merger agreement with Network Medical Management NLST 5.12% – News: Presenting at Needham Growth Conference on Jan. 12, 2017 DNAI 4.69% – News: Khang & Khang LLP investigating possible violations of federal securities laws SINO 4.18% – News: Launches new full-service logistics…

ThursdayDec 22, 2016 3:10 pm

NetworkNewsBreaks – Investors Applauding Akebia’s (NASDAQ: AKBA) Recent Alliance with Otsuka Pharmaceutical (OTSKF)

Shares of Akebia Therapeutics (NASDAQ: AKBA) are ticking higher in mid-day trade, following handsome gains on Tuesday after the company announced its collaboration and license agreement with Otsuka Pharmaceutical (OTC: OTSKF) for vadadustat in the U.S. The companies will equally share the revenue and commercialization costs of vadadusta for the treatment of anemia associated with chronic kidney disease. “Our alliance with Otsuka, one of the world’s innovative pharmaceutical leaders, also allows us to prepare an optimal launch of vadadustat, as we will equally share commercial responsibility. Otsuka brings a well-established commercial presence and infrastructure in the U.S., and we share…

ThursdayDec 22, 2016 1:47 pm

NetworkNewsBreaks – Inovio (NASDAQ: INO) Releases Early Clinical Results of Zika Vaccine

Inovio Pharmaceuticals (NASDAQ: INO) released results of its DNA-based Zika vaccine (GLS-5700) phase I trial designed to evaluate the safety, tolerability and induction and persistence of Zika specific antibody and T cell responses. In initial testing, Zika-naïve subjects in both low dose and high dose vaccine groups demonstrated Zika antigen-specific antibody responses after one or two vaccinations. The vaccine has been well tolerated and no significant safety concerns have been noted to date. “These early clinical results show that Inovio is on track to rapidly develop Zika countermeasures for this disease that has no currently existing vaccine or treatment. Our…

ThursdayDec 22, 2016 12:51 pm

NetworkNewsBreaks – Second Sight (NASDAQ: EYES): UK Government Greenlights Funding for Argus II “Bionic Eye” Implants

Second Sight Medical Products (NASDAQ: EYES) has made a groundbreaking achievement after advisors issued a positive recommendation to the UK Government’s healthcare funding authority for specialized services in England. For the first time in the UK, the publicly funded NHS system will fund blind patients with Retinitis Pigmentosa (RP) to receive treatment with Second Sight’s innovative Argus® II Retinal Prosthesis System (Argus II) “bionic eye.” A selective group of severely blind patients with RP will have access to Argus II, the world’s first and only routinely used treatment for severe blindness. The hospitals and Second Sight will provide follow up,…

ThursdayDec 22, 2016 12:49 pm

NetworkNewsBreaks – Tokai Pharmaceuticals (NASDAQ: TKAI) Trades Higher on Share Purchase Agreement with Otic Pharma

Tokai Pharmaceuticals (NASDAQ: TKAI) shares are up 38% mid-day after the company announced its definitive share purchase agreement with Otic Pharma Ltd., as well as the shareholders of Otic Pharma who will become the majority owners of Tokai. The transaction will result in a NASDAQ-listed company focused on the development and commercialization of products for ear, nose and throat (ENT) disorders. The emerging company will operate under the name OticPharma, Inc., and will be led by current Otic Pharma CEO Gregory J. Flesher. “Over the last several months, Tokai has conducted an extensive review of strategic alternatives aimed at maximizing…

WednesdayDec 21, 2016 1:58 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on December 21, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: NTFU 25.71% – News: Enters strategic partnership with JZ Marketing Group PTCO 45.71% – News: Purchased two oil and gas leases in Ohio VBIO 16.55%– News: DEA greenlights cannabinoid pharma development facility ESEA 9.94% – News: Will acquire Hull DY160 from Dayang shipyard SORL 5.79% – News: Increases 2016 FY earnings, sales guidance MSRT 3.44% – News: Appoints new CFO GLBL 3.25% – News: Posts 2015 financial results, files Form 10-K to regain regulatory…

WednesdayDec 21, 2016 1:16 pm

NetworkNewsBreaks – Calithera Biosciences, Inc. (NASDAQ: CALA), Bristol-Myers Squibb (NYSE: BMY) Collaborate to Assess Combination of Opdivo, CB-839

Calithera Biosciences (NASDAQ: CALA) and Bristol-Myers Squibb (NYSE: BMY) have entered into a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma (ccRCC). Preclinical data suggest that CB-839 – currently in phase 1/2 clinical studies - may enhance the effects of, and reverse tumor resistance to checkpoint inhibitors by altering the immune-suppressive microenvironment and encouraging an anti-tumor immune response. Opdivo is designed to overcome immune suppression. Under the collaboration, Calithera and Bristol-Myers will explore the potential of combining their agents with the goal of achieving improved and continual…

WednesdayDec 21, 2016 1:13 pm

NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Utilizes Key Data to Reach Target Demographics in China

Moxian (NASDAQ: MOXC) is securing a foothold in the O2O (online-to-offline) market in China by paying attention to who is using O2O services, and how active those users are on social media. “Unlike in the U.S. or Europe, where O2O is often considered to be items purchased online and picked up at a store, in China O2O includes a range of categories. O2O in China takes into account travel, accommodation, transport, dinner reservations, medical appointments, and virtually any services that are ordered or booked online but paid for at point of service. With this in mind, who is the primary…

WednesdayDec 21, 2016 1:11 pm

NetworkNewsBreaks – Sphere 3D (NASDAQ: ANY) Shares Climb After Subsidiary Launches 4TB RDX Cartridges

Shares are up 50% for Sphere 3D (NASDAQ: ANY) following the news of its wholly owned subsidiary, Tandberg Data, releasing its new 4TB RDX® cartridges. The new cartridges fit any RDX disk-based storage system, including Tandberg Data's QuikStor™ and QuikStation™. The 4TB RDX cartridge is designed for usage in data-intensive environments, such as professional workflow and archiving, hybrid cloud applications and database seeding. The company says it has the highest capacity RDX media on the market today, increasing maximum per cartridge storage by 30 percent. To view the full press release, visit: http://nnw.fm/j8mMz About Tandberg Data Tandberg Data is a…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks